Zyprexa Injections Investigated by FDA After 2 Deaths
The injectable form of the antipsychotic Zyprexa, called Zyprexa Relprevv (olanzapine pamoate) is under investigation by the US Food and Drug Administration after two patients died after receiving the injections.
According to the FDA, the patients received the appropriate dose and were monitored as required for three hours after the injection before being allowed to go home. However, both patients died 3-4 days after receiving the injections, so the FDA cannot be sure whether Zyprexa Relprevv was related to the deaths. Read Full PostZyprexa Injections Investigated by FDA After 2 Deaths originally appeared on About.com Bip...
Source: About.com Bipolar Disorder - June 3, 2013 Category: Psychiatry Source Type: news
A comparative study of beneficial effects of Olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial - Zarghami M, Sheikhmoonesi F, Ala S, Yazdani J, Farnia S.
BACKGROUND: Previous studies have shown a high prevalence of aggressive behavior in abstinent heroin users who are on methadone maintenance therapy (MMT) compared with healthy controls. Some studies suggest that olanzapine and valproate may be effective in... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - May 16, 2013 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial - Flint AJ, Iaboni A, Mulsant BH, Rothschild AJ, Whyte EM, Meyers BS.
OBJECTIVE: Observational studies report that selective serotonin reuptake inhibitor (SSRI) antidepressants are associated with an increased risk of falls in the elderly, but these studies may overestimate drug-specific risk because of confounding. A rand... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - May 11, 2013 Category: Global & Universal Tags: Age: Elder Adults Source Type: news
Study Looks at Metformin and Atypical Antipsychotics
It's well known that atypical antipsychotics (AAPs) such as Zyprexa and Seroquel cause weight gain. The prescribing information for all AAPs contains warnings that blood sugar should be monitored because this weight gain can be associated with diabetes, particularly in people with existing risk factors.
I had those risk factors - diabetes is prevalent in my family history. From various psychiatric medications, including Seroquel, I gained a total of 80 pounds (to 205 pounds) and weighed 190 when I became concerned about my blood sugar and contacted my doctor. Sure enough, I had developed diabetes. The doctor started me on...
Source: About.com Bipolar Disorder - April 22, 2013 Category: Psychiatry Source Type: news
Meta-Analysis: Adjunctive atypical antipsychotic treatment for major depressive disorder
Source: PLoS Medicine
Area: News
Atypical antipsychotic medications are widely prescribed for the adjunctive treatment of depression, yet little is known about their total risk-benefit profile. This meta-analysis reviewed the efficacy and safety profiles of aripiprazole, olanzapine/fluoxetine combination (OFC), quetiapine, and risperidone used for the adjunctive treatment of depression.
The study which included 14 randomised controlled trials found that:
. All four drugs had significant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48-2.73), OFC (OR, 1.42; 95% ...
Source: NeLM - Mental Health - March 13, 2013 Category: Psychiatry Source Type: news
Safely Prescribing Antipsychotic Medications
The use of antipsychotic medications has increased substantially over the last decade. Decisions about whether to prescribe them for particular patients should involve doctors, patients, and, when appropriate, family members. read more (Source: Psychology Today Anxiety Center)
Source: Psychology Today Anxiety Center - February 5, 2013 Category: Psychiatry & Psychology Authors: Eugene Rubin, M.D., Ph.D. Tags: Anxiety Depression Neuroscience Psychiatry antipsychotic medications anxiety disorders aripiprazole chlorpromazine delusions eating disorders hallucinations haloperidol hearing voices olanzapine personality disorders psychiat Source Type: news
Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance
INDIANAPOLIS, Jan. 29, 2013 /PRNewswire/ --
Fourth quarter revenue declined 1 percent driven by Zyprexa
patent expiration, largely offset by growth in other
products.
Fourth quarter earnings per share were $0.74 (reported), or $0.85... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2013 Category: Pharmaceuticals Source Type: news
Will Alkermes' Antipsychotic ALKS-3831 Become Another Tredaptive?
Second generation antipsychotic drugs, which were first discovered and developed in the 1990s, have been remarkably successful from a medical and commercial standpoint. One of the first, olanzepine (sold by Lilly as Zyprexa), had peak sales exceeding $5 billion before losing its patent protection in 2010. However, while effective in treating schizophrenia, olanzepine can cause dramatic weight gain in patients - a major problem in keeping patients on therapy as this weight gain can predispose patients to type 2 diabetes. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 15, 2013 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Information Links Lithium to Thyroid, Parathyroid Problems
A review in <i>The Lancet</i> found that in addition to the known potential for causing weight gain, taking lithium may increase the activity of the thyroid and parathyroid glands. Because of the increased risk for hyperparathyroidism, it is now recommended that doctors check blood calcium levels, an indicator for parathyroid activity, before beginning lithium therapy and periodically while the patient is taking lithium.<br /><br />
Lithium is a first-line treatment for bipolar disorder and may be used as add-on treatment for major depression.<p>
The review found that patients taking lithium...
Source: About.com Bipolar Disorder - January 14, 2013 Category: Psychiatry Source Type: news
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis
Source: Drug Safety
Area: Evidence > Medicines Management > References
Letter and the authors' reply (Drug Saf 2012;35(12):1183-1184) referring to a paper by Moteshafi, et al. (Drug Saf 2012;35(10):819-836). (8 refs.) (Source: NeLM - Mental Health)
Source: NeLM - Mental Health - January 7, 2013 Category: Psychiatry Source Type: news
Olanzapine in schizophrenia and affective disorders
Source: Drug Safety
Area: Evidence > Medicines Management > References
Letter and the authors' reply (Drug Saf 2012;35(12):1185-1186) referring to a paper by Moteshafi, et al. (Drug Saf 2012;35(10):819-836). (11 refs.) (Source: NeLM - Mental Health)
Source: NeLM - Mental Health - January 7, 2013 Category: Psychiatry Source Type: news
Racial-ethnic differences in incident olanzapine use after an FDA Advisory for patients with schizophrenia
Conclusions: After the FDA communication and consensus statement were issued, differences in ... (Source: NeLM - Mental Health)
Source: NeLM - Mental Health - January 3, 2013 Category: Psychiatry Source Type: news
